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Objective. To investigate the efficacy of RNAIII-inhibiting peptide (RIP) and nisin as prophylactic agents in a rat model of
vascular graft infection.
Design. Prospective, randomized, controlled animal study.
Materials. Two hundred and twenty adult male Wistar rats. Staphylococcus epidermidis ATCC 12228 and one clinical
isolate of methicillin-resistant S. epidermidis. Drugs: RIP, nisin and rifampin.
Methods. Graft infections were established in the dorsal subcutaneous tissue by implantation of 1 cm2 sterile Dacron grafts,
followed by topical bacterial inoculation: grafts were retrieved at 7 days. The study included a control group (without
inoculation) and two series composed of five groups for each staphylococcal strain: one contaminated group that did not
receive any antibiotic prophylaxis, three contaminated groups that received grafts soaked with 10 mg/l RIP, 10 mg/l nisin,
10 mg/l rifampin, or RIP þ nisin. The main outcome measure was the extent of bacterial at graft harvest.
Results. The bacterial counts for methicillin-resistant S. epidermidis on explanted grafts were 6.1 ^ 2.8 £ 102,
7.8 ^ 3.0 £ 103 and 5.5 ^ 2.9 £ 104 for RIP, nisin and rifampin, respectively. RIP and nisin used in combination reduced
the bacterial count to ,10. The results for S. epidermidis were similar.
Conclusions. RIP and nisin could be used in combination to coat medical devices to prevent drug resistant S. epidermidis
infections.
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Introduction
Bacteria that adhere to implanted medical devices play
an important role in industry and in modern medicine.
Since adherent microrganisms can become the cause of
persistent infections, it is an important problem that
has been the subject of numerous investigations.1 – 3
The bacteria encase themselves in a hydrated matrix of
polysaccharide and proteins, forming a slimy layer
known as a biofilm. Prevention of biofilm formation is
a necessary step in the successful prophylaxis of
medical device infections.1,3,4 Vascular prosthetic graft
infection is one of the most feared complications that
frequently results in prolonged hospitalization, organ
failure, amputation, and death.5,6
Coagulase-negative staphylococci are among the
most common pathogens that cause biomaterial-
associated infections. Staphylococcus epidermidis, a
skin commensal, is the most frequent cause of late-
appearing vascular graft infection in humans.4,6,7
Biofilm-based infections are rarely resolved. Anti-
biotics may suppress symptoms of infection by killing
free-floating bacteria, but fail to eradicate bacterial
cells still embedded in the biofilm.3 In addition, tissue
adjacent to the biofilm can undergo collateral damage
by immune complexes and neutrophils. For this
reason, the centerpiece of the antimicrobial strategy
remains prevention by using systemic and topical
antibiotics.1 – 4,8,9 Nevertheless, the development of
microorganism resistance to several antimicrobial
agents emphasizes the need to develop new drugs to
prevent graft-associated infections.10 – 13 Consequently,
several extended-spectrum or selective antimicrobial
agents are under investigation as new approaches in
the prevention of vascular prosthesis infections.
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In this study, we tested the efficacy of two peptides,
RIP and nisin that have proven activity against
staphylococci, and compared them to the standard
drug, rifampin. RIP is a heptapeptide YSPWTNF-NH2
having inhibitory activity against Staphylococcus aureus
and S. epidermidis.14 RIP inhibits staphylococcal
quorum sensing and in addition, it reduces bacterial
adherence to mammalian cells and to synthetic
materials. This indicates that it could be used as a
prophylactic and therapeutic agent against staphylo-
coccal infection.14 – 16 Nisin is a 34-residue-long peptide
belonging to the group A antibiotics and produced by
Streptococcus lactis subsp. Lactis. Nisin has antibacterial
activity against a wide range of Gram-positive bacteria
including several important contemporary multidrug-
resistant Gram-positive pathogens.17 – 19 Nisin has
been used in foods as a direct additive to inhibit the
growth of Gram-positive cells and spores. Nisin can
adsorb to surfaces, maintain its anti-bacterial activity
and kill adherent cells. Purified nisin has been
evaluated for its safety in vivo and has been found
harmless, or of very low toxicity in rat and guinea pig
models. Finally, in 1988, the Food and Drug Admin-
istration granted approval for the use of nisin in
pasteurized processed cheese spreads and established
the legal precedent for application of bacteriocins as
food additives in the US.17 – 19
RIP and nisin were tested for their ability to prevent
S. epidermidis graft infection in a well described
vascular graft rat model.20,21 Peptides were spon-
taneously bound to the graft, and their efficacy in
preventing graft infection was compared to rifampin,
an antibiotic commonly used for pre-coating grafts.20
Materials and Methods
Organisms
Methicillin-susceptible (MS) S. epidermidis ATCC 12228
(Oxoid S.p.A., Milan, Italy) and a clinical isolate of
methicillin-resistant (MR) S. epidermidis (Se10-01)
cultured from a patient with surgical wound infection
coming from Central Italy and admitted to the
Hospital Umberto I, Ancona, Italy, in February 2001.
Drugs
Bacterially derived nisin (Sigma-Aldrich S.r.l. Milan,
Italy) and RIP (Neosystem, Strasbourg, France) were
dissolved in distilled H2O at 20 times the required
maximal concentration. Rifampin (Sigma-Aldrich
S.r.l.) was dissolved in 50% methanol–50% acetone at
a concentration of 1 mg/ml. Fresh solutions were
made daily.
Binding of RIP and nisin to Dacron
To determine how much RIP impregnates Dacron,
fluorescein isothiocyanate (FITC)-RIP (10 mg/l) was
applied to 1 cm2 sterile collagen-sealed Dacron graft
(AlbograftTM, Sorin Biomedica Cardio, S.p.A., Saluggi
VC, Italy) for 20 min at room temperature. Fluor-
escence in unbound solution was determined at OD
485/530 nm in a Microplate Fluorescence Reader (FL
600, Bio-Tek, Vermont, USA) using KC4 software. The
binding level of nisin to Dacron was estimated using
UV spectroscopy. 1 cm2 collagen-sealed Dacron graft
(AlbograftTM, Sorin Biomedica Cardio, S.p.A., Saluggi
VC, Italy) was first washed with distilled water for
10 min. Then the Dacron was impregnated with 9-
fluorenylmethyl chloroformate (Fmoc)-nisin (10 mg/l)
for 20 min at room temperature. The absorbance of
Fmoc-nisin was measured at l 266 nm with UV–vis
spectrometer (Lambda 40P, Perkin–Elmer, Norwalk,
USA), either before or after impregnation.22
Antimicrobial susceptibility testing
The antimicrobial susceptibilities of the strains to
rifampin, RIP, and nisin were determined by the broth
microdilution method described by the National
Committee for Clinical Laboratory Standards.23 Mini-
mal inhibitory concentration (MIC) was taken as the
lowest antibiotic concentration at which observable
growth was inhibited. Experiments were performed in
triplicate.
Rat model
The study was approved by the animal research ethics
committee of the I.N.R.C.A. I.R.R.C.S., University of
Ancona, Ancona, Italy. Adult male Wistar rats (weight
range, 280–350 g) were studied. The study included a
control group (without graft inoculation) and two
series composed of five groups (MS1 to MS5 and MR1
to MR5) for each staphylococcal strain. Each of the
series included one contaminated group, three con-
taminated groups that received grafts soaked in RIP,
nisin or rifampin, and one contaminated group that
received grafts soaked with nisin þ RIP. Each group
contained 20 animals. Rats were anesthetized with
ether, the hair on the back was shaved, and the skin
cleansed with 10% povidone–iodine solution. One
subcutaneous pocket was made on each side of the
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median line by a 1.5 cm incision. Aseptically, 1-cm2
sterile collagen-sealed Dacron grafts (Albografte,
Sorin Biomedica Cardio, S.p.A., Saluggi VC, Italy)
were implanted into the pockets. Prior to implan-
tation, the Dacron graft segments were impregnated
with 10 mg/l RIP (MS2 and MR2), 10 mg/l nisin (MS3
and MR3), 10 mg/l rifampin (MS4 and MR4), 10 mg/l
RIP plus 10 mg/l nisin (MS5 and MR5). Drug
absorption on the graft was performed immediately
before implantation by soaking the graft for 30 min in
a sterile solution of the agents mentioned above. To
remove any non-adherent antimicrobial agent, each
graft was rinsed 1 min in 50 ml sterile saline before
implantation. The pockets were closed by means of
skin clips and sterile saline solution (1 ml) containing
S. epidermidis ATCC 12228 or the methicillin-resistant
strain S. epidermidis Se10-01 at a concentration of
2 £ 107 colony forming units/ml (cfu/ml) was inocu-
lated onto the graft surface by using a tuberculin
syringe to create a subcutaneous fluid-filled pocket.
The animals were returned to individual cages and
thoroughly examined daily. Toxicity was evaluated on
the basis of the presence of any drug related adverse
effects, i.e. local signs of perigraft inflammation,
anorexia, weight loss, vomiting, diarrhea, fever and
behavioral alterations. All grafts were explanted at 7
days following implantation.
Assessment of the infection
The explanted grafts were placed in sterile tubes,
washed in a sterile saline solution, moved into tubes
containing 10 ml of sterile phosphate-buffered saline
solution and sonicated (Fisher Scientific 300, PBI
International, Milan Italy) for 5 min to remove adherent
bacteria from the grafts. Quantitation of viable bacteria
was obtained by performing serial dilutions (0.1 ml) of
the bacterial suspension in 10 mM of sodium HEPES
buffer (pH 7.2) (Sigma-Aldrich, Milan, Italy) to minimize
the carryover effect and by culturing each dilution on
blood agar plates. All plates were incubated at 37 8C for
48 h and evaluated for the presence of the staphylococcal
strains. The organisms were quantitated by counting the
number of cfu/plate. The limit of detection for this
method was approximately 10 cfu/cm2.
Statistical analysis
MIC values are presented as the geometric mean of
three separate experiments. Quantitative culture
results from all groups are presented as mean ^
standard deviation and the statistical comparisons
between groups were made using analysis of variance
(ANOVA) on the log-transformed data. Significance
was accepted when the P value was #0.05.
Results
Binding of RIP and nisin to Dacron
To determine how much RIP and nisin bound to the
Dacron graft, the graft was soaked in FITC-RIP or
Fmoc-nisin and absorbance determined. These exper-
iments showed that when 1 cm2 Dacron was soaked in
a 10 mg/l RIP or 10 mg/l nisin solutions there was
binding of 25.9 mg ^ 3.6 of RIP or 35.2 ^ 4.1 mg of
nisin, respectively.
In vitro studies
Using the broth-microdilution method, rifampin
exhibited MICs of 0.25 and 4.00 mg/l for S. epidermidis
ATCC 12228 and S. epidermidis Se10-01, respectively. In
contrast, the two strains demonstrated similar suscep-
tibility patterns for nisin, which showed MICs of
4.00 mg/l for both strains. Finally, RIP did not
demonstrate any in vitro activity against either strain
(MICs &greater;128 mg/l).
In vivo studies
None of the animals included in the negative control
group (no inoculation of graft) had anatomic and
microbiological evidence of graft infection. On the
other hand, all 40 rats included in the groups MS1 and
MR1 demonstrated evidence of graft infection, with
4.8 £ 107 ^ 2.0 £ 107 cfu/cm2 graft and 5.1 £ 107 ^
1.3 £ 107 cfu/cm2 graft, respectively, but without
local signs of perigraft inflammation. Among the
groups treated with a single antimicrobial agent, the
groups MS2 and MR2 showed the lowest bacterial
growth, 5.2 £ 102 ^ 1.3 £ 102 cfu/cm2 graft and
6.1 £ 102 ^ 2.8 £ 102 cfu/cm2 graft, respectively. The
groups MS3 and MS4 demonstrated similar quantitat-
ive culture results with 6.2 £ 103 ^ 1.3 £ 103 cfu/cm2
graft and 5.8 £ 103 ^ 1.6 £ 103 cfu/cm2 graft, respect-
ively. In contrast, MR3 showed a lower bacterial
growth (7.8 £ 103 ^ 3.0 £ 103) than MR4 (5.5 £ 104 ^
2.9 £ 104). Finally, only the groups MS5 and MR5,
treated with the RIP þ nisin combination, showed no
evidence of staphylococcal infection, with quantitative
cultures below the limit of detection (Table 1). For all
treated grafts the bacterial counts were significantly
lower than for the untreated grafts. Interestingly,
RIP-treated group MR2 had a significantly higher
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bacterial count than the rifampin-treated group MR4.
The bacterial counts from the single agent treatment
groups (MS2 to MS4 and MR2 to MR4) were
significantly higher than the counts for grafts treated
with RIP þ nicin.
Finally, no agent appeared to have toxic side-effects.
No animal had clinical evidence of drug related
adverse effects, such as local signs of perigraft
inflammation, anorexia, weight loss, vomiting, diar-
rhea, fever and behavioral alterations.
The results and the statistical comparisons between
groups are summarized in Table 1.
Discussion
Recent studies on bacterial biofilm suggest that its
formation is the cause of a multicellular developmen-
tal process regulated by the exchange of chemical
signals between bacteria. It is well known that specific
gene products are required for the initial association of
bacteria with a surface and that during this process
several genes are turned on and off as bacteria move
onto a surface, suggesting a pathway of differen-
tiation.1,3,24 The recognition of biofilm formation as a
multicellular process is important because this insight
will allow new approaches for prevention and treat-
ment of the persistent infections stemming from
biofilm. Most or all the antibiotics currently used
were identified on the basis of their activity against
growing cultures of individual organisms. Screening
of existing or novel drugs selected for activity against
non-growing or biofilm organisms might yield anti-
microbial agents with clinical efficacy. New prophy-
lactic and therapeutic strategies could use analogues
of microbial signalling molecules that interfere with
cell-to-cell communication required for normal biofilm
formation, and proteins or peptides able to reduce
bacterial adherence. RIP falls into this category. It
interferes with cell-to-cell communication reducing
bacterial adhesion in the early exponential phase and
inhibiting toxins and virulence factors production in
the late exponential phase.14 As evidenced by MIC
results, RIP does not kill the bacteria, but eliminates
their ability to adhere and form a biofilm. RIP can,
therefore, be used for prevention of biofilm formation.
We explored the potential synergy of RIP with nisin,
a peptide from Streptococcus lactis. It is well known that
nisin exert very low toxicity, but even though the Food
and Drug Administration granted approval for its use
as food additives, in vivo report are lacking. Due to the
low toxicity of nisin and its high antimicrobial activity
against staphylococci, we decided to investigate, for the
first time in vivo, its activity in an animal model of
staphylococcal Dacron graft infection. Nisin has the
advantage that it adheres strongly to several synthetic
materials due to its particular chemical structure. It is
a cationic amphipilic peptide (electric charge
approximately þ 4) with several unusual dehydro
residues and thioether-bridged lanthionines.18,25 The
surface of several synthetic materials used by micro-
biologists and surgeons, such as polystyrene, polyte-
trafluoroethylene, and polyethylene terephthalate
(Dacron), bind this type of cationic molecules
strongly.26,27 As a result of this binding, the retention
of the biologically active molecules is not due to passive
entrapment in the plastic tissue but results from ionic
interaction between the anionic ligands and the cationic
compounds, thus allowing a longer adhesion on the
graft and improved anti-bacterial activity. In contrast, it
has been shown that if antimicrobial agents have an
insufficient number of positively charged residues,
they usually bind to the prosthetic graft via a protein
such as collagen, albumin and fibrin.28 – 32
When nisin and RIP were tested alone, RIP showed
the higher efficacy against both staphylococcal strains,
but only the combination of nisin and RIP was able to
completely inhibit bacterial growth, even when high
concentrations of bacteria had been inoculated on the
Dacron prostheses. Interestingly, rifampin was not
effective as RIP and nisin against the resistant strain,
indicating that the two peptides are good candidates
for treatment of drug-resistant staphylococci.
Previously, we have investigated the effects of RIP,
both alone and in combination with other cationic
Table 1. Efficacy of RIP, nisin, and rifampin against methicillin-
susceptible and methicillin-resistant Staphylococcus epidermidis
strains causing graft infection in a rat model
Group* Graft-bonded drug† Quantitative graft culture
(CFU/cm2)
Control – ,10
MS1 – 4.8 £ 107 ^ 2.0 £ 106
MS2 RIP‡ 5.2 £ 102 ^ 1.3 £ 102
MS3 Nisin‡ 6.2 £ 103 ^ 1.3 £ 103
MS4 Rifampin‡ 5.8 £ 103 ^ 1.6 £ 103
MS5 RIP-nisinc,d ,10
MR1 – 5.1 £ 107 ^ 1.3 £ 107
MR2 RIPc,e 6.1 £ 102 ^ 2.8 £ 102
MR3 Nisin‡ 7.8 £ 103 ^ 3.0 £ 103
MR4 Rifampin‡ 5.5 £ 104 ^ 2.9 £ 104
MR5 RIP-Nisinc,d ,10
*Each group was formed by 20 animals; MS methicillin-susceptible;
MR methicillin-resistant.
†The Dacron graft segments were impregnated with 10 mg/l RIP
(group 3), 10 mg/l nisin, 10 mg/l rifampin.
‡Statistically significant when compared with group MS1 or MR1
ðP , 0:001Þ:.
§Statistically significant when compared with groups MS2-MS4 or
MR2-MR4 ðP , 0:001Þ:.
kStatistically significant when compared with group MR4
ðP ¼ 0:007Þ:.
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peptides, against different multiresistant staphylococ-
cal strains.33 – 35 Data from these studies demonstrated
that the co-administration of agents able to reduce
bacterial adherence to prosthetic materials together
with agents able to kill the bacteria can be an useful
way to prevent vascular graft infection.
The present study confirms the usefulness of this
alternative approach for antimicrobial perioperative
chemoprophylaxis in vascular surgery.
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